Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.

  title={Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol.},
  author={William G Ondo and Philip A. Hanna and Joseph Jankovic},
  journal={The American journal of psychiatry},
  volume={156 8},
OBJECTIVE Tetrabenazine, a monoamine depleter and dopamine receptor blocker, is used to treat several hyperkinetic movement disorders. The authors studied the use of tetrabenazine for tardive dyskinesia. METHOD Twenty patients with tardive dyskinesia (mean duration = 43.7 months) were videotaped before and after tetrabenazine treatment. Randomized videotapes were scored with the motor subset of the modified Abnormal Involuntary Movement Scale (AIMS) by raters blind to pre- or posttreatment… 

Deutetrabenazine in the treatment of tardive dyskinesia.

Two pivotal clinical trials provide evidence that deutetrabenazine dosed 24-48 mg/day effectively controlled involuntary movements according to rating scales, and interim results of a long-term open-label study show continued efficacy and good tolerability, even in combination with baseline dopamine receptor blocking agents.

Tetrabenazine for the Treatment of Tardive Dyskinesia

Small trials indicate tetrabenazine may be effective for the treatment of tardive dyskinesia, however, larger, well-conducted trials are needed to confirm these findings.

Tetrabenazine in treatment of hyperkinetic movement disorders: an observational study

TBZ proved an effective and relatively well tolerated treatment in hyperkinetic disorders, with excellent results in HD, and was more common in OM dyskinesia, which may be related to higher age at TBZ initiation.

Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study

The combination of TBZ, CLONAZ and CLOZ is a rapid and beneficial option for the management of TD in psychotic patients and an augmentation effect probably played a role in the rapid alleviation of symptomatology.

Tetrabenazine Treatment in Movement Disorders

It is concluded that TBZ is a moderately effective treatment of a large variety of hyperkinetic movement disorders, with excellent effects in a subgroup with chorea and facial dystonia/dyskinesias.

Valbenazine for the Treatment of Adults with Tardive Dyskinesia.

Valbenazine is a relatively newer option for the treatment of tardive dyskinesia in adults and has limited toxicities making it an effective treatment regimen, but further research, including additional direct comparison studies, should be conducted to fully evaluate this drug's usefulness.

Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia

Deutetrabenazine is effective at decreasing dyskinesia in TD, but drug selection and cost-effectiveness between existing VMAT2 inhibitors are evolving areas of study.

Treatment Recommendations for Tardive Dyskinesia

Preventing tardive dyskinesia is of primary importance, and clinicians should follow best practice for prescribing antipsychotic medication, including limiting the prescription for specific indications, using the minimum effective dose, and minimising the duration of therapy.

Treatment of tardive dyskinesia with tetrabenazine or valbenazine: a systematic review.

Valbenazine appears to have fewer side effects and a more favorable once-daily dosing regimen for the treatment of TD, compared with tetrabenazine, and this systematic review was designed to update the evidence for TD treatment.

Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia.

Valbenazine and deutetrabenazine were demonstrated to be effective in decreasing AIMS scores and were well tolerated in randomized controlled trials and may be considered as a next-line option when traditional strategies are not feasible or are ineffective.



Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study

Tetrabenazine is a useful and safe therapeutic agent in some patients with hyperkinetic movement disorders and shows marked improvement in one patient with Huntington disease and two patients with congenital choreoathetosis.

Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias

Tetrabenazine is an effective and relatively safe drug for a variety of hyperkinetic movement disorders, and the choreatic movement disorders are most amenable to tetrABenazine therapy, but tardive and idiopathic dystonia may also be responsive.

Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine.

Haloperidol produced a statistically significant reduction in the frequency of oral dyskinesia, though the effect was most striking during the first two weeks; reversible extrapyramidal symptoms appeared to be negatively correlated with oral dysKinesia.

Long-term effects of tetrabenazine in hyperkinetic movement disorders

TBZ is an effective and safe drug for the treatment of a variety of hyperkinetic movement disorders and in contrast to typical neuroleptics, TBZ has not been demonstrated to cause tardive dyskinesia.

Treatment of involuntary movement disorders with tetrabenazine

Drowsiness, insomnia, and depression were the most conspicuous unwanted effects, and these may limit the clinical usefulness of the drug.

Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine.

It is demonstrated that tetrabenazine (Nitoman [Great Britain]), a dopamine-depleting agent, significantly reduces the frequency of abnormal mouth, jaw, and tongue movements at dosages up to 150 mg/day.

Tetrabenazine and movement disorders

Improvement occurred in 6 of 8 patients with Huntington disease, 6 of 10 with tardive dyskinesia, and 3 of 8 with dystonic disorders after treatment with tetrabenazine, and the drug was usually tolerated well.

Tetrabenazine in the treatment of Huntington's chorea and other hyperkinetic movement disorders.

Observations in 15 patients with various hyperkinetic disorders treated with tetrabenazine in doses up to 200 mgm.

The spectrum of depressive phenomena after spousal bereavement.

There is evidence that drugs that block 5-HT2 receptors as well as D2 receptors have better EPS profiles and risperidone at antipsychotic doses was better tolerated than haloperidol.

Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome

Tetrabenazine (which has both presynaptic monoaminedepleting effects and postsynaptic blocking action) was evaluated in nine patients and side effects included drowsiness, “nervousness”, depression, parkinsonism, and oculogyric crises in one, but all undesirable effects cleared with maintenance or reduction of the dosage.